Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics
PTGX Price/Volume Stats
| Current price | $25.57 | 52-week high | $33.34 |
| Prev. close | $26.11 | 52-week low | $13.72 |
| Day low | $25.35 | Volume | 517,500 |
| Day high | $26.39 | Avg. volume | 718,477 |
| 50-day MA | $28.44 | Dividend yield | N/A |
| 200-day MA | $21.71 | Market Cap | 1.49B |
PTGX Stock Price Chart Interactive Chart >
Protagonist Therapeutics, Inc. (PTGX) Company Bio
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.
Latest PTGX News From Around the Web
Below are the latest news stories about PROTAGONIST THERAPEUTICS INC that investors may wish to consider to help them evaluate PTGX as an investment opportunity.
Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ...In a notable insider transaction, President and CEO PATEL DINESH V PH D has sold 75,000 shares of Protagonist Therapeutics Inc (NASDAQ:PTGX), a clinical-stage biopharmaceutical company. |
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative ColitisNEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to ... |
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety SignalsLong term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis of PACIFIC Phase 2 study shows that rusfertide improves ... |
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with DeucravacitinibThe ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1Protagonist eligible to receive $115 million milestone upon achieving the co-primary endpoints in any ... |
Protagonist Therapeutics Reports Granting of Inducement AwardsNEWARK, CA / ACCESSWIRE / November 16, 2023 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2023, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer ... |
PTGX Price Returns
| 1-mo | -11.28% |
| 3-mo | 3.23% |
| 6-mo | 77.32% |
| 1-year | 8.99% |
| 3-year | -2.03% |
| 5-year | 144.22% |
| YTD | 11.51% |
| 2023 | 110.17% |
| 2022 | -68.10% |
| 2021 | 69.64% |
| 2020 | 185.96% |
| 2019 | 4.75% |
Loading social stream, please wait...